Epstein Secrets

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for Ix Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connections"' From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

"Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mrn/yr in sales for Co

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subj

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:43:38 +0000 agreed her frequent recommendati

ive opportunity and are reiterating our Buy rating. For MYL, little credit is given to the stock for Copaxone (especially with recent concerns over EpiPen pricing) & note that MYL has still yet to receive approval for lx Copaxone & is awaiting approval for 3TW. Sumant models $100mm/yr in sales for Cop